1/37
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced |
|---|
No study sessions yet.
pulmonary hypertension
pathological elevation in pulmonary artery pressure (vessels in the lungs)
pulmonary artery HTN
-fatal dz characterized by an increase in pulmonary arterial pressure w/ subsequent RV failure and death
-caused by destruction of small blood vessels in the lungs
-NOT caused by lung dz, primary L-sided heart dz, or large pulmonary emboli
Group 1: PAH
-pulmonary arteries themselves are diseased (thickened, narrowed, or remodeled)
-idiopathic PAH, connective tissue dz, congenital heart dz, drug-induced
-arteries are the issue
Group 2 - LHD
-left heart disease
-pressure backs up from the left side of the heart into the lungs
-left sided HF, mitral/aortic valve disease
-traffic jam from left heart
Group 3: lung dz/hypoxia
-chronic lung or low-oxygen conditions strain pulmonary vessels
-COPD, ILD, sleep apnea
-bad lungs, high pressure
Group 4: Chronic Thromboembolic PH
-old or recurrent blood clots block lung vessels and increase pressure
-chronic pulmonary emboli
-clots clog flow
Group 5: multifactorial/unclear
-mixed or rare causes that do not fit neatly elsewhere
-blood, systemic, or metabolic d/o
Pre-capillary HTN
-primary elevation of pressure in the pulmonary artery system alone --> caused by pulmonary vascular remodeling leading to increased pulmonary vascular resistance
Primary pre-capillary PAH
rare, disease of unknown etiology, idiopathic; vascular
Secondary Pre-capillary PAH
-complication of pulmonary, cardiac, and extrathoracic conditions
-often associated with emphysema, collagen vascular dz, congenital heart dz, pulmonary embolism, HIV, liver dz, diet drugs
Postcapillary HTN
-elevations of pressure in the pulmonary venous and pulmonary capillary systems --> result of an increase in pulmonary venous pressure in left-sided heart dz
-think group 2
Pulmonary HTN incidence
-general pop w/ primary PH = 1-2 per 1 million persons
-scleroderma = 10-15%
-COPD (severe) --> 90% have mild to mod PH, 3-5% have severe PH
-OSA = 15-20%
-HIV = 1 per 200 (0.5%)
Uncontrollable pulm HTN RF
-age --> most dxs: 30-60; idiopathic PAH is common in younger adults
-FH --> PAH, PE
-blood clotting d/o
-genetic d/o --> incl congenital heart dz
Controllable pulm HTN RF
-overweight
-asbestos exposure
-high altitude
-drug use --> certain weight loss drugs, illegal drugs, SSRIs
Anesthesia and PH
-PH significantly increases risks d/t anesthesia
-increases perioperative mortality d/t: severe hypoxemia, acute RIGHT heart failure, circulatory collapse
PH prognosis
-highly variable
-could take 2+ years to correctly dx
-severe and progressive dz: emphasizes the importance of early dx and aggressive therapy
PH mortality
-survival rate (w/o tx from time of R-sided heart catheterization) --> median 2.8 years
-common cause of death: lower resp infxn, cor pulmonale (right heart failure)
-life expectancy has improved d/t dx techniques and specialized therapies
PH Triad
-atypical chest pain (pleuritic pain, pain w/ moving)
-syncope
-increasing DOE
PH S/S
-early: chest pain, DOE, fatigue, tachycardia, RUQ abd pain, decreased appetite
-Late sx: light-headed, esp during activity, syncope, LE edema, cyanosis
-result from inability to increase CO during demand
PH DDx
-aortic stenosis
-ASD
-Cardiomyopathies
-mitral regurg
-mitral stenosis
-VSD
-COPD
-PE
-Emphysema
-ILD
-OSA
-restrictive lung dz
Chest XR - PH
-m/c finding --> enlarged hilar vessels that rapidly prune into periphery and RVH
-right ventricle fills anterior airspace on lateral view
ECG - PH
-higher the PA pressure = more sensitive the ECG
-may demonstrate signs of RV hypertrophy
Transthoracic Echocardiogram - PH
-make a preliminary dx by estimating the pressures in the R heart and assessing heart function
-used to r/o other heart conditions w/ similar sxs
PFTs - PH
-may identify PH cause
V/Q Scan - PH
-test for PE
-helps distinguish CTEPH from other causes of PH
CT scan - PH
-helps dx lung dzs that may lead to PH like COPD, pulmonary fibrosis
Cardiac Catheterization - PH
-gold standard for PH dx (right heart cath)
-directly measures the pressure inside the pulmonary arteries
-should be done in all pts at least 1x to confirm a pt's PH dx
serum Lab Eval - PH
-BNP can assess strain on heart and may monitor response to tx
-most predictive noninvasive variable of survival
Sleep Studies - PH
-help dx sleep apnea, which can be a cause of PH
Lung Biopsy - PH
-establish dx of primary PH and determine grade and reversibility
ABGs - PH
-hypocapnia is an independent marker of mortality, esp in PH
PH - Dx Approach
-Group 2/3 dz --> TTE to screen, then PFT w/ ABG --> if these don't reveal anything --> do V/Q Scan to check for Group 4 dz --> if defect is present, do pulm angiography or CT
-Findings from hx, PX, CXR, ECG
-2D R sided cardiac catheterization - gold standard
-pts should also be screened for OSA
-lastly, lab studies to check for group 1 dz (PAH)
PH - Dx Use and Sequence
-start with noninvasive, then can do more invasive if necessary
-refer to PH center if severe
-echocardiogram - most useful initial imaging test
-serum lab tests
-CXR, ECG, V/Q scan, High res CT, Cardiac catheterization
PH Tx Goal
-improve: NYHA heart functional class by 1-2 classes, 6MWD to >400m, CO (baseline and exercise), QOL, survival
-decreased RAP and BNP
General PH Tx
-early tx recommended for underlying cause
-supportive tx
-advanced vasodilatory tx
-preventive care
-balloon atrial septostomy
-lung or heart transplant --> severe PAH
lung or heart transplant
-reserved for pts with severe PAH (only hope for some)
-typically, only NYHA functional class 4 after 3 months of tx with epoprostenol (50% survival after 5 years)
PH - Tx meds
-oxygen --> reduce hypoxemic pulmonary arterial vasospasm
-anticoagulation --> decrease clot formation
-diuretics --> makes breathing easier
-K+ --> to replace what may be lost while taking diuretics
-inotropic agents --> improve pumping ability of heart
PH - vasodilator
pts with PH produce less nitric oxide (vasodilator), so they may need a vasodilator to help them out